Analysis

Tenax Therapeutics, Inc. (TENX) Stock Analysis

Tenax Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to TENX.

websiteTENX/analysis/TENX

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to TENX.

Stock profile

Ticker

TENX

Asset type

Stock

Market cap

$318.3M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Tenax Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • TENX primary listing
  • YBO0
  • A3EVQN

Latest Tenax Therapeutics, Inc. news

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by ...

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage phar...

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experienceCHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Te...

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (...

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial

Research sections

Valuation

Review valuation context for Tenax Therapeutics, Inc..

Future growth

Review future growth context for Tenax Therapeutics, Inc..

Past performance

Review past performance context for Tenax Therapeutics, Inc..

Financial health

Review financial health context for Tenax Therapeutics, Inc..

Dividend

Review dividend context for Tenax Therapeutics, Inc..

Management

Review management context for Tenax Therapeutics, Inc..

Ownership

Review ownership context for Tenax Therapeutics, Inc..

Other information

Review other information context for Tenax Therapeutics, Inc..

Community

Review community context for Tenax Therapeutics, Inc..